267 related articles for article (PubMed ID: 15542540)
1. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
Pantophlet R; Wilson IA; Burton DR
Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
3. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
Pantophlet R; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
[TBL] [Abstract][Full Text] [Related]
4. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
5. Comparing antigenicity and immunogenicity of engineered gp120.
Selvarajah S; Puffer B; Pantophlet R; Law M; Doms RW; Burton DR
J Virol; 2005 Oct; 79(19):12148-63. PubMed ID: 16160142
[TBL] [Abstract][Full Text] [Related]
6. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
7. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.
Kang SM; Quan FS; Huang C; Guo L; Ye L; Yang C; Compans RW
Virology; 2005 Jan; 331(1):20-32. PubMed ID: 15582650
[TBL] [Abstract][Full Text] [Related]
8. Designed cyclic permutants of HIV-1 gp120: implications for envelope trimer structure and immunogen design.
Saha P; Bhattacharyya S; Kesavardhana S; Miranda ER; Ali PS; Sharma D; Varadarajan R
Biochemistry; 2012 Mar; 51(9):1836-47. PubMed ID: 22329717
[TBL] [Abstract][Full Text] [Related]
9. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
10. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
Pantophlet R; Ollmann Saphire E; Poignard P; Parren PW; Wilson IA; Burton DR
J Virol; 2003 Jan; 77(1):642-58. PubMed ID: 12477867
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X
Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016
[TBL] [Abstract][Full Text] [Related]
12. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
Ahmed FK; Clark BE; Burton DR; Pantophlet R
Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583
[TBL] [Abstract][Full Text] [Related]
13. Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.
Pashov A; MacLeod S; Saha R; Perry M; VanCott TC; Kieber-Emmons T
Glycobiology; 2005 Oct; 15(10):994-1001. PubMed ID: 15917430
[TBL] [Abstract][Full Text] [Related]
14. Antibody neutralization and escape by HIV-1.
Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
[TBL] [Abstract][Full Text] [Related]
15. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
[TBL] [Abstract][Full Text] [Related]
18. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
19. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
Kwong PD; Doyle ML; Casper DJ; Cicala C; Leavitt SA; Majeed S; Steenbeke TD; Venturi M; Chaiken I; Fung M; Katinger H; Parren PW; Robinson J; Van Ryk D; Wang L; Burton DR; Freire E; Wyatt R; Sodroski J; Hendrickson WA; Arthos J
Nature; 2002 Dec; 420(6916):678-82. PubMed ID: 12478295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
